Biontech
-
{
- All
- News
- Videos
-
'Positive' Trial For Pfizer-BioNTech Covid-Flu Jab
"A pivotal phase three trial evaluating these lead formulations is expected to be initiated in the coming months," they said.
-
Pfizer-BioNTech To Test Combined Vaccine For Covid, Flu
Pfizer-BioNTech said Thursday they will test a combined coronavirus and influenza vaccine, which could potentially pave the way for better inoculation uptake for both illnesses.
-
US Is Considering Second Covid Booster For 65+
Pfizer and BioNTech announced Tuesday they had formally asked the United States drug regulator for emergency approval of a second booster shot of their Covid vaccine for people aged 65 and older.
-
World "Better Prepared" For Covid Variants: Vaccine Maker BioNTech
The world is becoming "better prepared" to deal with future variants of the coronavirus, the CEO and co-founder of German vaccine-maker BioNTech told AFP Thursday, as the company works on an Omicron-specific shot.
-
Pfizer-BioNTech Begin Trials For An Omicron-Specific Vaccine
Pfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific Covid-19 vaccine in adults aged up to 55, the companies said in a statement Tuesday.
-
For Omicron, Third Dose Of Covid Shot May Be Needed: Pfizer
Pfizer and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world.
-
Three Doses "Effective" Against Omicron: Pfizer/BioNTech
Two doses of the BioNTech and Pfizer coronavirus vaccine may not be enough to protect against the Omicron variant, the companies warned Wednesday, but stressed it was "still effective" after a third jab.
-
Shots Should Protect From Worst Of Omicron, Says Big Vaccine-Maker
The current generation of Covid-19 vaccines probably will still protect against severe disease in people infected by the omicron variant, BioNTech SE Chief Executive Officer Ugur Sahin said.
-
BioNTech Is Working On An 'Omicron' Version Of Its Covid Shot
BioNTech SE is working to adapt its Covid-19 vaccine to address the 'Omicron' variant and expects to have a new version ready within 100 days if necessary.
-
BioNTech And Pfizer Expect New Variant Impact Data "Within 2 Weeks"
Germany's BioNTech said Friday it was urgently studying how well the coronavirus vaccine it developed with Pfizer protects against the new B.1.1.529 variant detected in South Africa.
-
What To Know About COVID-19 Vaccine For US Children
The US Food and Drug Administration is considering authorizing a COVID-19 vaccine for children aged 5 to 11. The vaccine from Pfizer Inc and BioNTech SE has been available in the United States to kids aged 12 to 15 since May.
-
US To Weigh Authorisation Of Pfizer Covid Vaccine For Children Aged 5-11
An expert panel will weigh authorization of Pfizer Inc and BioNTech's COVID-19 vaccine for children aged 5 to 11 on Tuesday as it prepares to vote on a recommendation for the US Food and Drug Administration.
-
Third Dose Of Pfizer's COVID-19 Vaccine 95.6% Effective: Study
A third dose of the vaccine against COVID-19 developed by Pfizer/BioNTech is 95.6 percent effective against symptomatic infection.
-
Pfizer Submits Initial Data For Covid Vaccine Booster Authorization
Pfizer Inc and its German partner BioNTech SE have submitted to U.S. regulators the initial data from an early-stage trial toward seeking authorization of a booster dose of their COVID-19 vaccine, the drugmakers said on Monday.
-
"Fill And Finish": Pfizer BioNTech To Produce COVID-19 Vaccines In South Africa
Covid vaccine makers BioNTech and Pfizer said Wednesday they would produce their jab in South Africa from 2022, a first for the continent that could see much-needed immunisation drives pick up speed.
-
'Positive' Trial For Pfizer-BioNTech Covid-Flu Jab
"A pivotal phase three trial evaluating these lead formulations is expected to be initiated in the coming months," they said.
-
Pfizer-BioNTech To Test Combined Vaccine For Covid, Flu
Pfizer-BioNTech said Thursday they will test a combined coronavirus and influenza vaccine, which could potentially pave the way for better inoculation uptake for both illnesses.
-
US Is Considering Second Covid Booster For 65+
Pfizer and BioNTech announced Tuesday they had formally asked the United States drug regulator for emergency approval of a second booster shot of their Covid vaccine for people aged 65 and older.
-
World "Better Prepared" For Covid Variants: Vaccine Maker BioNTech
The world is becoming "better prepared" to deal with future variants of the coronavirus, the CEO and co-founder of German vaccine-maker BioNTech told AFP Thursday, as the company works on an Omicron-specific shot.
-
Pfizer-BioNTech Begin Trials For An Omicron-Specific Vaccine
Pfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific Covid-19 vaccine in adults aged up to 55, the companies said in a statement Tuesday.
-
For Omicron, Third Dose Of Covid Shot May Be Needed: Pfizer
Pfizer and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world.
-
Three Doses "Effective" Against Omicron: Pfizer/BioNTech
Two doses of the BioNTech and Pfizer coronavirus vaccine may not be enough to protect against the Omicron variant, the companies warned Wednesday, but stressed it was "still effective" after a third jab.
-
Shots Should Protect From Worst Of Omicron, Says Big Vaccine-Maker
The current generation of Covid-19 vaccines probably will still protect against severe disease in people infected by the omicron variant, BioNTech SE Chief Executive Officer Ugur Sahin said.
-
BioNTech Is Working On An 'Omicron' Version Of Its Covid Shot
BioNTech SE is working to adapt its Covid-19 vaccine to address the 'Omicron' variant and expects to have a new version ready within 100 days if necessary.
-
BioNTech And Pfizer Expect New Variant Impact Data "Within 2 Weeks"
Germany's BioNTech said Friday it was urgently studying how well the coronavirus vaccine it developed with Pfizer protects against the new B.1.1.529 variant detected in South Africa.
-
What To Know About COVID-19 Vaccine For US Children
The US Food and Drug Administration is considering authorizing a COVID-19 vaccine for children aged 5 to 11. The vaccine from Pfizer Inc and BioNTech SE has been available in the United States to kids aged 12 to 15 since May.
-
US To Weigh Authorisation Of Pfizer Covid Vaccine For Children Aged 5-11
An expert panel will weigh authorization of Pfizer Inc and BioNTech's COVID-19 vaccine for children aged 5 to 11 on Tuesday as it prepares to vote on a recommendation for the US Food and Drug Administration.
-
Third Dose Of Pfizer's COVID-19 Vaccine 95.6% Effective: Study
A third dose of the vaccine against COVID-19 developed by Pfizer/BioNTech is 95.6 percent effective against symptomatic infection.
-
Pfizer Submits Initial Data For Covid Vaccine Booster Authorization
Pfizer Inc and its German partner BioNTech SE have submitted to U.S. regulators the initial data from an early-stage trial toward seeking authorization of a booster dose of their COVID-19 vaccine, the drugmakers said on Monday.
-
"Fill And Finish": Pfizer BioNTech To Produce COVID-19 Vaccines In South Africa
Covid vaccine makers BioNTech and Pfizer said Wednesday they would produce their jab in South Africa from 2022, a first for the continent that could see much-needed immunisation drives pick up speed.
